North America Continuous Glucose Monitoring Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

The North America Continuous Glucose Monitoring Market was valued at USD 5.1 billion in 2024 and is estimated to grow at a CAGR of 16.1% to reach USD 22.6 billion by 2034.

Growing Adoption of CGM Sensors

The sensors segment accounted for a significant share in 2024. These sensors are essential for capturing real-time glucose levels from interstitial fluid and transmitting accurate data to devices or smartphone applications. As users seek enhanced comfort, longer wear duration, and minimal calibration requirements, manufacturers are focusing on advancing sensor technology. Innovations such as extended wear sensors, flexible materials, and pre-calibrated solutions are fueling this segment's expansion. The upward trend underscores a broader movement toward user convenience, particularly for individuals managing diabetes outside of traditional healthcare facilities.

Increasing shift toward homecare settings

The homecare segment is expected to experience steady growth between 2025 and 2034, driven by a rising preference for remote monitoring and self-managed care. Patients are increasingly turning to CGM systems to track glucose levels in real time from the comfort of their homes. These systems not only support daily disease management but also enable seamless data sharing with healthcare providers and family members through connected digital platforms. This trend is minimizing the need for frequent clinical visits and empowering individuals to take a more proactive and independent role in their diabetes care.

U.S. to Emerge as a Lucrative Region

U.S. continuous glucose monitoring (CGM) market held a significant share in 2024, driven by rising diabetes prevalence, growing patient awareness, and strong technology adoption across healthcare systems. With the Centers for Disease Control and Prevention (CDC) estimating over 37 million Americans living with diabetes, the demand for real-time glucose monitoring solutions is escalating. Market leaders are responding to this need with next-generation CGM devices that offer extended sensor life, smartphone compatibility, and seamless integration with insulin delivery systems. Market growth is further supported by favorable reimbursement policies, consumer demand for personalized healthcare, and a significant shift toward home-based and remote monitoring technologies.

Major players involved in the North America continuous glucose monitoring (CGM) market are i-SENS, Glucovation, Medtronic, Nemaura Medical, F. Hoffmann-La Roche, Dexcom, A. Menarini Diagnostics, Senseonics, Abbott Laboratories, Insulet Corporation, and Sinocare.

Companies competing in the North America continuous glucose monitoring (CGM) market are focusing on innovation, partnerships, and patient-centric solutions to strengthen their market position. Strategic collaborations with digital health platforms, pharmacy chains, and insurance providers are helping major players expand reach and accessibility. Many firms are investing heavily in R&D to develop non-invasive or minimally invasive CGM solutions that improve comfort and accuracy while reducing maintenance. Mergers and acquisitions remain a favored strategy for expanding product portfolios and gaining a competitive edge.